Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omidac-D
- Development stage
- Phase 4
- Lead developer
- SBM Enterprises
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Omidac-D is a fixed-dose combination pharmaceutical product marketed by SBM Enterprises, an Indian pharmaceutical company. It contains omeprazole, a proton pump inhibitor (PPI), and domperidone, a prokinetic agent and dopamine D2 receptor antagonist. Omeprazole reduces gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cells. Domperidone increases gastrointestinal motility and lower esophageal sphincter pressure by blocking peripheral dopamine receptors, which helps in relieving symptoms of nausea and vomiting often associated with acid-related disorders. The combination is primarily indicated for the treatment of gastroesophageal reflux disease (GERD), functional dyspepsia, and peptic ulcers where a prokinetic effect is beneficial.
- Brand names
- Omidac-D
- Other names
- omeprazole + domperidoneOmidac D
02
Targets
DRD2 (Dopamine D2 Receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on Omidac-D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omidac-D.